Edward Tenthoff
Stock Analyst at Piper Sandler
(3.36)
# 979
Out of 5,147 analysts
198
Total ratings
42.86%
Success rate
5.03%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.94 | +209.28% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $13.27 | +50.72% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $53.57 | +28.80% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.32 | +72.41% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $17.75 | +108.45% | 4 | Jan 14, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $100 → $110 | $63.27 | +73.86% | 14 | Jan 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintains: Overweight | $6 → $8 | $1.51 | +429.80% | 1 | Jan 9, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $27.93 | +61.12% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $91.35 | +36.84% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $8.38 | +174.46% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.81 | +231.49% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $332.92 | +46.88% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $9.41 | +27.52% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.49 | +167.26% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $12.72 | +17.92% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $60.14 | +74.59% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $20.47 | -2.30% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.37 | +410.95% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $15.62 | +207.30% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.85 | +51.42% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $19.00 | +310.53% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.77 | +134.93% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.28 | +2,750.88% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.74 | +2,584.92% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.20 | +150.00% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.28 | +971.05% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.48 | +305.41% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.71 | +192.40% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $57.98 | +327.73% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.44 | +2,516.28% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $8.74 | +1,959.50% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.77 | +162.37% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $5.73 | +545.72% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $7.32 | +160,131,047.54% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $766.92 | -53.84% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $496.83 | -34.99% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.22 | +144.62% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $44.06 | -18.29% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.48 | +1,589.19% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.61 | +24,571.05% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.19 | +7,459,359.46% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $781.67 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $12.35 | +8,515.38% | 2 | Apr 15, 2013 |
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.94
Upside: +209.28%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $13.27
Upside: +50.72%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $53.57
Upside: +28.80%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.32
Upside: +72.41%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $17.75
Upside: +108.45%
Arrowhead Pharmaceuticals
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $63.27
Upside: +73.86%
Acrivon Therapeutics
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.51
Upside: +429.80%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $27.93
Upside: +61.12%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $91.35
Upside: +36.84%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $8.38
Upside: +174.46%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.81
Upside: +231.49%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $332.92
Upside: +46.88%
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $9.41
Upside: +27.52%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.49
Upside: +167.26%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $12.72
Upside: +17.92%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $60.14
Upside: +74.59%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $20.47
Upside: -2.30%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.37
Upside: +410.95%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $15.62
Upside: +207.30%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.85
Upside: +51.42%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $19.00
Upside: +310.53%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.77
Upside: +134.93%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.28
Upside: +2,750.88%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.74
Upside: +2,584.92%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.20
Upside: +150.00%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.28
Upside: +971.05%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.48
Upside: +305.41%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.71
Upside: +192.40%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $57.98
Upside: +327.73%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.44
Upside: +2,516.28%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $8.74
Upside: +1,959.50%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.77
Upside: +162.37%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $5.73
Upside: +545.72%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $7.32
Upside: +160,131,047.54%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $766.92
Upside: -53.84%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $496.83
Upside: -34.99%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.22
Upside: +144.62%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $44.06
Upside: -18.29%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.48
Upside: +1,589.19%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.61
Upside: +24,571.05%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.19
Upside: +7,459,359.46%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $781.67
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $12.35
Upside: +8,515.38%